Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daire Hanna"'
Autor:
Valerie E. Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, Neha Chopra, Ekin Bamac, Meera Desai, Yuk-Chun Lam, Sabiq Dipro, Ruhi Kanani, Jack Benson, William Wilson, Thomas A. Fox, Kai-Keen Shiu, Martin Forster, John Bridgewater, Daniel Hochhauser, Khurum Khan
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). This study investigated the outcomes of patients
Externí odkaz:
https://doaj.org/article/5c0177a3f1404d148a4de2c9ec8fe517
Publikováno v:
Critical reviews in oncology/hematology. 171
The use of BReast CAncer (BRCA) mutations as biomarkers for sensitivity to DNA damage response (DDR) targeted drugs and platinum agents is well documented in breast and gynaecological cancers. More recently the successful use DDR targeted therapies i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f05add8afe60b3ef731510bdb714542
https://pubmed.ncbi.nlm.nih.gov/35124199
https://pubmed.ncbi.nlm.nih.gov/35124199
Autor:
Valerie E. Crolley, Daire Hanna, Nalinie Joharatnam-Hogan, Neha Chopra, Ekin Bamac, Meera Desai, Yuk-Chun Lam, Sabiq Dipro, Ruhi Kanani, Jack Benson, William Wilson, Thomas A. Fox, Kai-Keen Shiu, Martin Forster, John Bridgewater, Daniel Hochhauser, Khurum Khan
Publikováno v:
SSRN Electronic Journal.
Background: Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). We investigated the outcomes of patients receivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::009126015d071b3873f6566779136066
https://doi.org/10.2139/ssrn.3696625
https://doi.org/10.2139/ssrn.3696625
Autor:
Valerie Crolley, Kai-Keen Shiu, William R. Wilson, Daniel Hochhauser, Nalinie Joharatnam-Hogan, Ruhi Kanani, Jack Benson, Neha Chopra, John Bridgewater, Thomas Andrew Fox, Khurum Khan, Ekin Bamac, Yuk-Chun Lam, Martin Forster, Sabiq Dipro, Daire Hanna, Meera Desai
Publikováno v:
Journal of Clinical Oncology. 39:10567-10567
10567 Background: One of the major challenges with COVID-19 has been the changes to cancer services, including changes to the type of systemic anti-cancer treatment being delivered to patients. There needs to be a better understanding of which cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e71f9a2d08cb69c697fb27da19c3ce1b
https://doi.org/10.1200/jco.2021.39.15_suppl.10567
https://doi.org/10.1200/jco.2021.39.15_suppl.10567
Autor:
A. Guppy, Alicia Okines, A. Lerner, Apostolos Konstantis, Judy King, Daire Hanna, E. Takeuchi, Rebecca Roylance, B. Sanderson, Fharat Raja, K. Keshwani, F. Rehman, E. Spurrell, R. Murphy, C. Westbury, E. Sharkey, R.E. Board, Michael Flynn
Publikováno v:
Clinical Oncology. 32:e167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3ce7fb5d61bf1a113e8dc6e358e5fc7
https://doi.org/10.1016/j.clon.2020.02.009
https://doi.org/10.1016/j.clon.2020.02.009
Autor:
Ravindhi Murphy, Michael Flynn, Apostolos Konstantis, Elena Takeuchi, Benjamin Sanderson, Fharat Raja, Rebecca Roylance, Farah Rehman, Amy Elizabeth Guppy, Daire Hanna, Emma Spurrell, Karim Keshwani, anna lerner, Elizabeth Sharkey, Charlotte Westbury, Alicia Frances Clare Okines, Ruth E. Board, Judy King
Publikováno v:
Journal of Clinical Oncology. 37:e12525-e12525
e12525 Background: Fulvestrant is a selective oestrogen receptor (ER) down regulator used to treat hormone receptor-positive advanced breast cancer in postmenopausal women. It is used at various time points in treatment. However, variations in fundin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::859a2a238edbe3ee396ca0ce3b087d8d
https://doi.org/10.1200/jco.2019.37.15_suppl.e12525
https://doi.org/10.1200/jco.2019.37.15_suppl.e12525